New Insights into Inflammation and Its Role in Cardiometabolic Disease to Be Explored at the Cardiometabolic Health Congress

BOSTON, Oct. 8, 2012 – Attendees of the Cardiometabolic Health Congress (CMHC) will learn the latest about the pathophysiological connections between inflammation and cardiovascular disease as well as the clinical implications of new research in this area during a keynote address titled “Inflammation and Cardiometabolic Risk: Translating the Science into Clinical Practice.”

The presentation will be given by two leading experts in the field from Boston's Brigham and Women's Hospital: Dr. Peter Libby, who is chief of cardiovascular medicine there, and Dr. Paul Ridker, who is director of the Center for Cardiovascular Disease Prevention at the hospital. The keynote session is scheduled for 8:10 am to 9:30 am on Friday, Oct. 12, 2012.

Dr. Libby will discuss the latest research into the basic science of inflammation and its links to adipose tissue dysfunction, insulin resistance and atherogenic disease. Dr. Ridker will explain the clinical implications of this new information. He will provide an update on his own and others' clinical studies in this field and discuss how markers of inflammation can be used to asses patients' cardiovascular risk and guide clinical decision-making.

This session will be moderated by CMHC co-chair Christie Ballantyne, MD. “These sessions will provide clinicians state-of-the-art knowledge as to the basic mechanisms involving inflammation which link obesity, diabetes and cardiovascular disease,” Dr. Ballantyne said, “along with an update on new therapies that are being tested to treat inflammation and prevent heart attack and stroke.”

The 7th Annual CMHC, featuring 64 world-renowned expert faculty, 15 scientific sessions, 16 corporatesupported and corporate-sponsored symposia, and approximately 30 CME continuing medical education credit hours, will convene Oct. 10-13, 2012, in Boston. The event is co-chaired by George L. Bakris, MD; Christie M. Ballantyne, MD; Robert H. Eckel, MD; and Jay S. Skyler, MD, MACP. The CMHC provides the most advanced-level cardiometabolic education encompassing a multitude of risk factors, including obesity, Type 2 diabetes, cardiovascular disease, dyslipidemia, atherosclerosis, hypertension, thrombosis, acute coronary syndrome, chronic kidney disease and related comorbidities.

Visit www.cardiometabolichealth.org for information on accreditation, faculty, association and industry supporters, and registration.

For more information, contact Brittany Henry at info@cardiometabolichealth.org or 877-571-4700.